NEW YORK, June 13, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceuticalcompany focused on adjunctive cancer care and critical care drug products, is presenting to investors at the 2017 Marcum MicroCap Conference on June 15. The Marcum conference is a highlight on the annual investment community
Citius is scheduled to present at 2:30 PM. Leonard Mazur, the Executive Chairman of Citius, along with Myron Holubiak, President and Chief Executive Officer, will jointly deliver the corporate presentation and provide an overview of the company including recent business developments. To arrange a meeting with management, please contact Mr. Andrew Scott: firstname.lastname@example.org.
Citius is currently advancing two product candidates: Mino-Lok which is entering Phase 3 trials, and a Corticosteroid/Lidocaine formulation that is entering Phase 2b. The markets for these products are large and underserved, and provide unique exclusive positions for Citius.
The Marcum MicroCap Conference (www.marcummicrocap.com) is a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. More than 2000 investors and other participants from every segment of the microcap marketplace attend each year, including venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, and buy- and sell-side analysts, as well as senior executive teams from presenting companies and service providers to the microcap marketplace.
The conference is presented by Marcum LLP, a top national accounting and advisory firm registered with the Public Company Accounting Oversight Board (PCAOB). Marcum's Assurance Division provides the most up-to-date service and guidance on SEC accounting and reporting issues. Services include Financial Statement Audits in accordance with PCAOB standards; Tax Compliance and Advisory Services; Due Diligence; Agreed-Upon Procedures and Other Attest Work; Internal Audit Services; Sarbanes-Oxley Section 404 Compliance Services and Software; Technical Accounting Assistance; and IPO Assistance. For more information, visit www.marcumllp.com.
About Citius Pharmaceuticals, Inc. Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. www.citiuspharma.com
Contact: Andrew Scott, Vice President, Corporate Development email@example.com 646-522-8410
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-presents-at-the-2017-marcum-microcap-conference-300473142.html
SOURCE Citius Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All